March 6, 2017 / 12:17 PM / 5 months ago

TG Therapeutics' leukemia drug clears hurdle in key study

1 Min Read

March 6 (Reuters) - TG Therapeutics Inc said a late-stage study testing a combination of its experimental cancer drug ublituximab and AbbVie Inc's Imbruvica was superior to Imbruvica alone in high-risk patients with a common form of leukemia.

The trial involved adult patients with high-risk chronic lymphocytic leukemia, who had undergone at least one prior therapy. (Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below